The platinum-based drugs cisplatin, carboplatin and oxaliplatin are often used for chemotherapy, but drug resistance is common. The prediction of resistance to these drugs via genomics is a challenging problem since hundreds of genes are involved. A possible alternative is to use mass spectrometry to determine the propensity for cells to form drug-DNA adducts-the pharmacodynamic drug-target complex for this class of drugs. The feasibility of predictive diagnostic microdosing was assessed in non-small cell lung cancer (NSCLC) cell culture and a pilot clinical trial. Accelerator mass spectrometry (AMS) was used to quantify Lung cancer is the worldwide leading cause of cancer-related deaths, with the majority of cases comprising of non-small cell lung cancer (NSCLC). 1,2 Most NSCLC patients present at advanced stages and are treated with platinum (Pt)-based chemotherapy as a first line or maintenance therapy. Despite the wide-spread use, the response rate is <30%.
toxicities and costs and also delaying the use of other potentially useful chemotherapy regimens for several months. Therefore, assays for prospective identification of chemosensitivity prior to initiation of therapy are much needed. Numerous groups have used gene expression analysis and other genomic approaches to gain insights into the mechanisms of Pt-based drug resistance. This led to the discovery of hundreds of genes that are involved in cellular response toward these drugs. [4] [5] [6] However, translating these findings into a clinically useful test for predicting tumor resistance prior to the initiation of chemotherapy has proven to be difficult.
Cisplatin and carboplatin are commonly used in the treatment of NSCLC and many other cancer types. 7 Both drugs kill cells mainly through formation of intra-and interstrand DNA crosslinks (called adducts), which induce cell death via apoptosis or necrosis (Fig. 1a) . [8] [9] [10] [11] The adduct levels are governed by various factors including genetics, tumor microenvironment, kidney function, overall patient health and others. 12, 13 The relationship between therapy-induced drug-DNA adduct levels and clinical response has been reported for various cancers, including NSCLC. 10, [14] [15] [16] In some studies, a positive correlation of adduct level in normal surrogate cells (e.g., PBMC) and good clinical outcome have been observed, [16] [17] [18] whereas other reports failed to show such a correlation, possibly due to different study designs, drug regimes, analytical methods employed and small numbers of patients. 19, 20 Despite the previous contradictory reports, drug-DNA adduct levels as pharmacodynamic (PD) end points remain potentially more informative and useful than genomic analysis of drug response, particularly for cytotoxic chemotherapy agents. Accelerator mass spectrometry (AMS) is an ultrasensitive technique for measuring rare isotopes such as 14 C, which relies on dissociation of the sample into CO 2 or graphite followed by isotope ratio analysis in a small particle accelerator. The resulting ratio data allow calculation of the labeled drug concentration in tissues, blood, protein or nucleic acids at concentrations that are difficult or impossible to measure with other techniques. AMS therefore enables human studies with radiolabeled drug while circumventing the need for toxic drug or radiation exposures. 4, 21, 22 Carboplatin is easily labeled with a 14 C atom, and therefore detectable by AMS, whereas cisplatin is unable to be detected by AMS since it cannot be labeled with a 14 C atom. However, both drugs form the same final drug-DNA diadduct crosslink structures and are sometimes used interchangeably in clinical practice because clinical cross-resistance is common. 23 AMS specifically detects carboplatin-DNA monoadducts, since the 14 C-label in the cyclobutane dicarboxylate (CBDCA) group is released once the diadduct is formed (Fig. 1a) . Since drug-DNA monoadducts are the precursors of all other types of platinum-based drug-DNA adducts, we hypothesize that carboplatin-DNA monoadduct levels are predictive of carboplatin or cisplatin cytotoxicity, and that microdose-induced adduct levels are biomarkers of drug response to cytotoxic chemotherapy agents. 24 We have previously reported that relatively high levels of microdose-induced monoadducts correlated with high cytotoxicity of carboplatin in cancer cell lines from different cancer types. 24 We report herein investigation of carboplatin microdosing with six NSCLC cell lines and six NSCLC patients.
Materials and Methods

Chemicals
Unlabeled carboplatin (CARBOplatin V R , 10 mg/mL) was obtained from Hospira (Lake Forest, IL 14 C-labeled and unlabeled drug were used to minimize the usage of radiocarbon and achieve the different specific activities required for microdoses and therapeutic doses. Drug solutions for the indicated experiments were prepared immediately before use.
Cell lines and cytotoxicity assay
Six human NSCLC cell lines (H23, H460, H727, HCC827, H1975 and A549) were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured with the recommended medium unless otherwise specified. Their key characteristics are summarized in Supporting Information spectrophotometer, the purity was ensured by obtaining a 260/280 nm OD ratio of approximately 1.9. All DNA samples were submitted to Lawrence Livermore National Laboratory (LLNL) for AMS analysis of radiocarbon content using an established protocol. 27 Ten micrograms of DNA per sample was converted to graphite and measured by AMS for 14 C quantification as previously described. Triplicate sets of AMS experiments were performed for each cell line and time point. The data were plotted as carboplatin-DNA monoadducts per 10 8 nucleotides (nt) over time.
Molecular analysis
Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, Valencia, CA) following manufacturer's instructions. cDNA was synthesized from 500 ng of total RNA using the SuperScript V R III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Real-time PCR was conducted using the SYBR V R GreenER TM qPCR SuperMix (Invitrogen) and an iQ5 Real-Time PCR detection system (BioRad, Hercules, CA) for ERCC1 with b-actin as a reference gene. 28 Previously reported primers and optimized PCR conditions were used for each gene. The software package Q-Gene was used to determine the mean normalized expression (MNE) for each gene for three independent experiments and the MNE, along with the standard error, was plotted using GraphPad Prism 5 version 5.03 for Windows (GraphPad Software, San Diego CA). ]carboplatin administered as a microdose was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Patient response to chemotherapy was evaluated using RECIST criteria for correlation to carboplatin-DNA monoadduct frequency. The carboplatin dose for human chemotherapy was calculated using the Calvert formula with an AUC of 6. Therefore, individual patients were given a microdose of [ 7 dpm/kg of body weight) containing a total carboplatin dose at 1% of their therapeutic dose by a 2-min bolus intravenous (IV) infusion. Unlabeled carboplatin and [ 14 C]carboplatin were mixed immediately before dosing and injected through the peripheral vein at one arm. Peripheral blood specimens were drawn into BD Vacutainer CPT TM tubes with sodium citrate (Becton Dickinson) from the other arm at specified time points before and after the administration of the microdose. Tubes were immediately placed on ice and PBMC were isolated within 2 hr of collection by centrifugation according to manufacturer's instruction. A proportion of total plasma was used for LSC PK determination. Outcomes related to chemotherapy (including response and adverse events) were collected and correlated with carboplatin-DNA monoadduct data. 
Tumor Markers and Signatures
Statistical analysis
All statistical analyses were performed using GraphPad Prism TM software (GraphPad Software Inc., CA, USA) using a two-tailed Student's t test or when appropriate a 1-way ANOVA with Bonferroni's post hoc test. A p values below 0.05 was considered statistically significant. All experiments were carried out at least in triplicate in order to enable statistically significant comparisons of the results. All results are expressed as the mean 6 SD unless otherwise noted. A simple correlation of the adduct levels and response is reported.
Results
Comparison of NSCLC cell line sensitivity to carboplatin and cisplatin
Cisplatin and carboplatin form the same DNA crosslinks or diadducts (Fig. 1a) and clinical cross resistance is common. We proposed that the sensitivity of cell cultures to these two drugs might be similar. If so, the carboplatin microdosing approach described in this project could potentially be applied to the study in cellular sensitivity to cisplatin, since only carboplatin can be labeled with 14 C. Therefore, we compared the publicly available cytotoxicity data from the NIH Developmental Therapeutics Program (http://dtp.nci.nih.gov/ docs/compare/compare.html) (IC 50 or growth inhibition of 50%) of cisplatin and carboplatin in the NCI-60 NSCLC cell lines (Fig. 2 A549 , EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI-H522 and LXFL 529) and six NSCLC cell lines (Fig. 2, H23, H460 , H727, HCC827, H1975 and A549) that are used in our study for AMS analysis. DNA monoadduct levels induced by microdose and therapeutic concentrations of carboplatin in cell culture are linearly proportional DNA damage induced by therapeutically relevant doses (100 mM) or microdoses (1 mM) of carboplatin was determined through the AMS analysis of purified genomic DNA. To mimic the in vivo carboplatin half-life of 1.1-5.9 hr 26 the six NSCLC cell lines were treated for 4 hr and drug-DNA monoadduct levels were measured over a period of 24 hr (Fig. 3) .
There was a time-dependent increase in carboplatin-DNA monoadduct levels during the first 4 hr of incubation with microdose ( Fig. 3a) or therapeutic (Fig. 3b) concentrations of carboplatin followed by a gradual decrease over the subsequent 20 hr of incubation in drug-free medium. Peak adduct levels varied considerably between different cell lines even though all cell lines showed the same overall trend with respect to reaching a maximum adduct level and a gradual decrease after the drug was removed. Carboplatin-DNA monoadduct level at each time point in the microdosing group ranged from 1 to 10 monoadducts per 10 8 nucleotides (nt) and are approximate 100-fold lower adduct levels then the therapeutic group which ranged from 100-1,000 monoadducts per 10 8 nt (Fig. 3c) . Linear regression analysis showed the monoadduct levels induced by the two carboplatin doses were highly linear and statistically significantly correlated (R 2 5 0.95, p < 0.0001, Fig. 3d ), suggesting that the nontoxic microdosing approach can be used to predict the DNA monoadduct levels induced by therapeutic carboplatin.
Correlation of monoadduct levels and resistance to pt analogs
We correlated carboplatin-DNA monoadduct levels from both doses over 24 hr to the IC 50 data for each cell line (Fig.  4) . At each time point, the three most resistant cell lines A549, H1975 and HCC827 had lower carboplatin-DNA monoadduct levels than the three most sensitive cell lines H23, H460 and H727 (Figs. 4a and 4b and Supporting Information 
ERCC1 expression does not correlate with cellular sensitivity toward carboplatin or cisplatin
Quantitative analysis of ERCC1 expression in NSCLC tissue has been evaluated as a predictive biomarker for Pt-based chemotherapy in the clinic. 32 We determined ERCC1 expression by quantitative RT-PCR (Fig. 5a ) and correlated cisplatin (Fig.  5b) and carboplatin (Fig. 5c) IC 50 values of six NSCLC cell lines levels to the ERCC1 transcripts. Contrary to the inverse correlation of AUC with IC 50 values, there was no such an association between the ERCC1 expression in these six cell lines (p 5 0.950 and 0.686 for cisplatin and carboplatin, respectively).
A pilot diagnostic feasibility trial in human NSCLC patients
To assess the possibility to use microdosing to predict clinical outcome in NSCLC patients a clinical feasibility trial was initiated at UC Davis. A total of 21 patients were accrued, including 14 bladder cancers, 6 NSCLC and one mediastinal mass that was subsequently identified as Hodgkin's lymphoma. This article only discusses the data for NSCLC patients. The bladder cancer data were published separately, along with a supporting mouse study. 33 Of the 6 NSCLC patients that completed the microdosing and blood sampling, only three received subsequent full dose platinum based chemotherapy and could be evaluated for clinical response. The enrolled NSCLC patients in this pilot study included two males and four females with the age ranging from 51 to 72 years. The patients' characteristics are summarized in Supporting Information Table 2 .
With the microdose composition of [
14 C]carboplatin of 10 7 dpm/kg and a total carboplatin dose of 1% of the therapeutic dose (target AUC of 6), the 14 C-signal in DNA isolated from PBMC was approximately 10-100 times the background, which allowed accurate adduct measurement by AMS (Fig. 6 ). As expected, no microdose-associated adverse events were observed in any of the patients. The administered diagnostic [
14 C]carboplatin microdose appears to be safe in this patient population. In comparison to the annual effective radiation dose equivalent from natural internal sources of 1.6 mSv per person, 34 and a radiation exposure for an abdominal CT scan of 10 mSv, 35 the average administration of the diagnostic microdose was not >0.1 mSv.
Immediately following the blood draws, whole plasma was isolated for PK analysis via LSC. The PK of the diagnostic microdoses (Fig. 6a) showed biphasic elimination kinetics, with an initial T 1/2a (absorption and distribution) of 0.63-0.95 hr and T 1/2b (elimination) of 6.7-11.2 hr, which are similar to the published values. 26, [36] [37] [38] [39] At 24 hr after dosing, over 99% of 14 C label was cleared from the blood, suggesting this is the optimal time for biopsy with little concern for 14 C contamination.
Carboplatin-DNA monoadduct levels in genomic DNA from PBMC was chosen as a surrogate biomarker for analysis in tumor since several studies showed that platinum-based drug-DNA adducts in PBMC correlate with tumor response to chemotherapy, and because blood samples are easy to obtain. [16] [17] [18] [40] [41] [42] [43] [44] Radiocarbon content in the DNA was measured by AMS according to published protocols. 27 The levels of carboplatin-DNA monoadducts were readily detectable and ranged from 0.23 to 1.30 monoadducts per 10 8 nucleotides ( Fig. 6b and Supporting Information table 2). Three patients received subsequent platinum-based chemotherapy within 4 weeks after the microdosing procedure and clinical response could be correlated with adduct level (Fig. 6b) . One patient responded to chemotherapy (green symbols and line) whereas two patients showed stable disease or progression (red symbols and lines). At 24 hr, the responding patient exhibited higher PBMC monoadduct level (1.30 monoadducts/10 8 nt) than the two nonresponders (0.837 and 0.232 monoadducts/10 8 nt, respectively). However, the nonresponder with stable disease (red square symbols) showed the highest AUC (27.9 monoadducts/10 8 nt/hr) compared to the other nonresponder (11.4 monoadducts/10 8 nt/hr) and the responder (25.2 monoadducts/10 8 nt/hr). Adduct correlation to clinical outcome was not possible for three patients that underwent the microdosing procedure but that did not receive subsequent chemotherapy. Although the adduct level difference between response groups are not yet statistically significant, the early trend associating DNA monoadduct levels with patient response in encouraging.
Even though most of the [ 14 C]carboplatin was cleared from blood over 24 hr, monoadduct levels were readily measurable in DNA isolated from PBMC and tumor tissue. However, more patients need to be accrued to determine if monoadduct levels are dependent upon tissue type and are predictive of clinical response in NSCLC.
There was no significant correlation between the plasma half-life values (T 1/2a and T 1/2b ) and 24 hr PBMC drug-DNA monoadduct levels (Supporting Information Fig. 2 ), suggesting that the intracellular mechanisms predominate in the formation and repair of DNA damage rather than serum PK.
Discussion
We determined the feasibility of a diagnostic microdosing approach for the study of cellular sensitivity to cisplatin and carboplatin. Our data support the idea that microdoseinduced carboplatin-DNA monoadduct levels are predictive of response to either cisplatin or carboplatin. There was a significant linear correlation between cisplatin and carboplatin cell IC 50 values in a panel of NSCLC cell lines. The IC 50 values for both drugs also significantly correlated with carboplatin-DNA monoadduct levels for each cell line. We also observed that carboplatin-DNA monoadduct levels induced by therapeutically relevant concentrations of carboplatin significantly correlated with those formed by microdoses.
The positive correlation of adduct levels to IC 50 was superior compared to ERCC1 mRNA levels (Figs. 4 and 5) . ERCC1 was previously shown to correlate with resistance to platinum-based chemotherapy in NSCLC. 32 However, this protein is only one of many that participate in the major DNA repair pathways that interact with platinum-DNA adducts such as nucleotide excision repair, mismatch repair and recombinational repair. High levels of ERCC1 indicate the capability of fast DNA repair and probably confer resistance to Pt therapy in some patients. However, enhancement of nucleotide excision repair by ERCC1 may not be relevant if other cellular drug resistance mechanisms predominate. Although other DNA repair mechanisms certainly act upon platinum-DNA adducts, the use of the related gene expression or protein levels as biomarkers of response have not proven to be clinically useful (reviewed in Ref. 45 ). For example, ERCC1 antibodies are known to have lot-to-lot variation in substrate binding. A prospective phase III trial including 275 patients with Stage IV lung cancer failed to validate RRM1 tumor expression as a biomarker of platinum-based treatment response. BRCA1 mRNA levels in tumor tissue also failed to predict platinum resistance in 287 Stage IV NSCLC patients. Of the other multivariate panels for NSCLC, few have been replicated in independent cohorts for prognostic value, and none were externally validation for predictive value. Clearly, such tests still need substantial additional validation before inclusion into routine practice for cytotoxic chemotherapy. 45 ERCC2 single nucleotide polymorphisms (SNPs) and clinical outcome in NSCLC have been intensively studied. However, inconsistent and in some cases contradictory results have been published. For example, the results of one study, where the rs50872 locus variation was linked to poorer response and outcomes, 46 could not be duplicated by another group, where it was found to be a favorable marker. 47 In another prospective study, no correlation of ERCC2 SMP with chemotherapy response was found, only a significant association with radiotherapy-derived toxicity was established. 48 Other mechanisms include, but are not limited to, decreased drug uptake, increased efflux, drug inactivation by cellular antioxidants such as glutathione and others (Fig.  1b) . 4 In the six cell line panel we examined, carboplatin-DNA monoadduct levels were superior predictors of cellular resistance compared to ERCC1 expression levels (Fig. 4) .
Diagnostic microdosing is an attractive concept due to the simplicity of measuring a single marker that is influenced by a large array resistance factors. Furthermore, measurement of drug-DNA adduct levels may be useful as a tool for better understanding DNA repair pathways of clinical relevance. For example, the combination of carboplatin with DNA repair inhibitors such as a poly ADP ribose polymerase (PARP) may be most efficacious in patients with a propensity for forming high levels to carboplatin-DNA adducts or those patients with rapid DNA repair. Mouse and clinical studies have already shown that ABT-888, an oral PARP inhibitor, potentiates the antitumor activity of carboplatin. 49, 50 Our preclinical cell line data form the foundation of a currently active feasibility microdosing trial aimed at determining whether carboplatin-DNA monoadduct levels in PBMC and tumor tissue correlate with the response to carboplatin-based chemotherapy in NSCLC and bladder cancer. Our pilot study showed that a diagnostics feasibility study can be performed in patients without any detectable toxicity associated with the microdose. This pilot study was not designed to demonstrate statistical significance of carboplatin-DNA adduct frequency as a biomarker, but still yielded some encouraging results (Fig. 6) . First, we developed protocols for conducting a clinical trial with a 14 C-labeled drug and processing samples for AMS analysis. Based on this effort, we decided to perform the biopsy at 24 hr after dosing. At this time point, there were large inter-patient variations in drug-DNA adduct levels and the [ 14 C]carboplatin concentration in plasma was low, minimizing the possibility of contamination. Second, we defined a clinically useful of carboplatin microdose formulation consisting of 1% of the therapeutic dose of carboplatin and 10 7 dpm/kg of body weight of labeled drug-enough to detect carboplatin-DNA adducts but with minimal clinically acceptable radiation exposure to the patient. We were able to correlate carboplatin-DNA monoadduct levels with clinical response in three patients. One patient with the highest adduct levels after 24 hr had a positive clinical response, whereas the two patients with lower adduct levels did not respond. Patient 13 was potentially an outlier with respect to a very high initial binding of carboplatin to DNA followed by a rapid decrease in signal over time. Additional accruals are needed to better understand this observation.
Conclusion
We developed a highly sensitive AMS-based assay that can possibly identify cellular sensitivity to platinum-based drugs prior to toxic treatment. Based on this pilot study, a diagnostics feasibility clinical trial is currently in progress with enough power for statistical analysis to determine if carboplatin-DNA monoadduct levels correlate with cancer resistance.
